• organizations:Viridian Therapeutics
Viridian reports positive phase 3 data on veligrotug for chronic TED
Pipeline

Viridian reports positive phase 3 data on veligrotug for chronic TED

Latest THRIVE-2 study findings detail a favorable safety profile, shorter dosing regimen, and a promising diplopia response and resolution rate.
Viridian reports positive topline data from phase 3 TED trial
Pipeline

Viridian reports positive topline data from phase 3 TED trial

VRDN-001 (now veligrotug) achieves all primary and secondary endpoints as company plans to submit a BLA in 2025. 
Viridian completes patient enrollment for THRIVE-2 chronic TED trial
Pipeline

Viridian completes patient enrollment for THRIVE-2 chronic TED trial

Second phase 3 trial in the IGF-IR pipeline is evaluating VRDN-001, previously reported to reduce disease signs and symptoms after just two infusion sessions. 
Viridian to initiate two phase 3 studies for chronic TED
Pipeline

Viridian to initiate two phase 3 studies for chronic TED

VRDN-003, an IGF-IR monoclonal antibody, will be evaluated as a subcutaneous injection administered every 4 or 8 weeks.
Viridian reports positive data from ongoing trial of VRDN-001 for chronic TED
Business

Viridian reports positive data from ongoing trial of VRDN-001 for chronic TED

Safety and tolerability profile matches with previous data; company shares plans for subcutaneous program.
Positive data reported in ongoing phase 1/2 trial of VRDN-001 for TED
Research

Positive data reported in ongoing phase 1/2 trial of VRDN-001 for TED

Viridian Therapeutics announced the release of positive topline, 6-week data from its third, low-dose cohort.
Positive data reported in phase ½ trial of TED therapy
Pipeline

Positive data reported in phase ½ trial of TED therapy

Viridian Therapeutics released positive topline clinical data from 2 cohorts of its phase 1/2 clinical trial analyzing VRDN-001 for thyroid eye disease (TED).